Literature DB >> 22726275

IgG3 deficiency and severity of 2009 pandemic H1N1 influenza.

Emiko Sakai1, Takehisa Yamamoto, Katsusuke Yamamoto, Yoshimi Mizoguchi, Hiroshi Kaneno, Mai Ihashi, Mika Takano, Kaori Anzai, Tetsuo Kase, Tsunesuke Shimotsuji.   

Abstract

BACKGROUND: The severity of the 2009 pandemic H1N1 influenza (H1N1 pdm 09) in immune deficient children is unknown. The aim of the present study was to investigate this in a case of complete IgG3 deficiency complicated by pneumonia and asthma attack.
METHODS: The clinical parameters of the IgG3 deficiency patient were compared with those of four control patients using 95% confidence intervals. These control patients were selected from 71 patients admitted due to pneumonia or bronchitis caused by H1N1 pdm 09, and were chosen according to age, absence of pretreatment with oseltamivir before admission, presence of a past history of asthma, use of antibiotics, and combination of inhalation of a beta2 agonist and treatment with i.v. methylprednisolone for asthma attack.
RESULTS: The IgG3 deficiency patient had significantly longer duration of admission and period of oseltamivir, with a significantly decreased pulse oxygen saturation and increased maximum serum C-reactive protein, creatine kinase and urinary excretion of β2-microglobulin/creatinine, compared with the controls (P < 0.05).
CONCLUSIONS: Complete IgG3 deficiency is possibly associated with severity of the clinical course of pneumonia and asthma attack in children suffering from H1N1 pdm 09.
© 2012 The Authors. Pediatrics International © 2012 Japan Pediatric Society.

Entities:  

Mesh:

Year:  2012        PMID: 22726275     DOI: 10.1111/j.1442-200X.2012.03691.x

Source DB:  PubMed          Journal:  Pediatr Int        ISSN: 1328-8067            Impact factor:   1.524


  3 in total

Review 1.  Emerging Infections and Pertinent Infections Related to Travel for Patients with Primary Immunodeficiencies.

Authors:  Kathleen E Sullivan; Hamid Bassiri; Ahmed A Bousfiha; Beatriz T Costa-Carvalho; Alexandra F Freeman; David Hagin; Yu L Lau; Michail S Lionakis; Ileana Moreira; Jorge A Pinto; M Isabel de Moraes-Pinto; Amit Rawat; Shereen M Reda; Saul Oswaldo Lugo Reyes; Mikko Seppänen; Mimi L K Tang
Journal:  J Clin Immunol       Date:  2017-08-07       Impact factor: 8.317

2.  Investigating the effect of AS03 adjuvant on the plasma cell repertoire following pH1N1 influenza vaccination.

Authors:  J D Galson; J Trück; D F Kelly; R van der Most
Journal:  Sci Rep       Date:  2016-11-16       Impact factor: 4.379

3.  Robust and prototypical immune responses toward influenza vaccines in the high-risk group of Indigenous Australians.

Authors:  Luca Hensen; Thi H O Nguyen; Louise C Rowntree; Timon Damelang; Marios Koutsakos; Malet Aban; Aeron Hurt; Kim L Harland; Maria Auladell; Carolien E van de Sandt; Anngie Everitt; Cath Blacker; Damian A Oyong; Jessica R Loughland; Jessica R Webb; Bruce D Wines; P Mark Hogarth; Katie L Flanagan; Magdalena Plebanski; Adam Wheatley; Amy W Chung; Stephen J Kent; Adrian Miller; E Bridie Clemens; Peter C Doherty; Jane Nelson; Jane Davies; Steven Y C Tong; Katherine Kedzierska
Journal:  Proc Natl Acad Sci U S A       Date:  2021-10-12       Impact factor: 11.205

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.